Clinical trials: Relapsed Leukemia
Healthy
Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers
A first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of ZE50-0134 administered orally in healthy volunteers.
- Trial name
- NCT06787131
- Testing
- Rabeprazole 20 mg, Itraconazole (200 mg)
- Where
- Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Lomond Therapeutics Holdings, Inc.
Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia, in Relapse
Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia
This Phase 1 Study is an open-label, non-randomized, dose escalation, safety, efficacy, pharmacokinetic, and pharmacodynamic evaluation study of INA03 administered as a single agent IV infusion every 2 weeks to patients ≥18 years…
- Conditions
- Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukaemia Recurrent
- Trial name
- INA03 (NCT03957915)
- Testing
- INA03 administration
- Where
- 3 sites in France
- Volunteers
- 33 people
- Sponsor
- Institut Paoli-Calmettes
Bladder Cancer, Cervical Cancer
Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy
RATIONALE: Motivational counseling may help prevent pregnant women from smoking again after pregnancy. PURPOSE: This randomized clinical trial is studying three different types of counseling to see how well they work in…
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00310115
- Testing
- Smoking Prevention Usual Care, Counseling Intervention
- Where
- United States
- Volunteers
- 469 people
- Sponsor
- M.D. Anderson Cancer Center
Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
This phase II trial studies how well anti-cluster of differentiation (CD)19 monoclonal antibody MOR00208 and lenalidomide work in treating patients with relapsed, refractory, or previously untreated chronic lymphocytic leukemia…
- Conditions
- Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
- Trial name
- NCT02005289
- Testing
- MOR00208, lenalidomide, Correlative Studies
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Leukemia, Hairy Cell Leukemia
Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease
RATIONALE: The CAT-8015 immunotoxin can bind tumor cells and kill them without harming normal cells. This may be an effective treatment for hairy cell leukemia(HCL) that has not responded to chemotherapy, surgery or radiation…
- Conditions
- Leukemia, Hairy Cell Leukemia, HCL
- Trial name
- NCT00462189
- Testing
- Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy
- Where
- 5 sites in United States, Poland and 1 more
- Volunteers
- 40 people
- Sponsor
- Cambridge Antibody Technology
Myeloid Leukemia
Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia
The purpose of this study is to assess safety and tolerability of multiple ascending doses of AZD1152 and to assess effect of AZD1152 on the rate of complete remission in patients with relapsed acute myeloid leukaemia.
- Trial name
- NCT00497991
- Testing
- AZD1152
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 65 people
- Sponsor
- AstraZeneca
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
The NexCAR19 study is a national, open-label, multicenter Phase 2-3 clinical trial designed to evaluate the efficacy and safety of the anti-CD19 chimeric antigen receptor (CAR) T-cell product, Talikabtagene Autoleucel, in…
- Conditions
- Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), High-grade B-cell Lymphoma (HGBCL)
- Trial name
- NexCAR19 (NCT07502118)
- Testing
- Talikabtagene Autoleucel
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Health Institutes of Turkey
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia
This study will evaluate the safety and effectiveness of a combination of two antibodies, apolizumab and rituximab (Rituxan ), in treating B-cell lymphomas and chronic lymphocytic leukemia.
- Conditions
- Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
- Trial name
- NCT00022971
- Testing
- Apolizumab, Rituximab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
B Cell Lymphoma, B-cell Acute Lymphoblastic Leukemia
CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia
The primary objective of this study is to evaluate the safety and clinical activity of anti-CD19 Chimeric Antigen Receptor T cells (KD-019 CAR-T)infusion in the treatment of relapsed/refractory B-cell Lymphoma and B-cell acute…
- Trial name
- NCT03854994
- Testing
- Anti-CD19 CAR-T Cells Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Yan'an Affiliated Hospital of Kunming Medical University
Non-hodgkin Lymphoma
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT05206357
- Testing
- Epcoritamab
- Where
- 41 sites in United States, Australia and 12 more
- Volunteers
- 17 people
- Sponsor
- Genmab
Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
The purpose of this study is to test the safety of 19(T2)28z1xx CAR T cells in people with relapsed/refractory B-cell cancers. The researchers will try to find the highest dose of 19(T2)28z1xx CAR T cells that causes few or mild…
- Conditions
- Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT04464200
- Testing
- 19(T2)28z1xx CAR T cells
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Lymphocytic Leukemia, Relapse Leukemia
Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy
Observational study aimed at describing the characteristics and outcome of CLL patients who started treatment with venetoclax-based regimens according to the local label outside clinical trials in Italy in a period of time…
- Conditions
- Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia
- Trial name
- NCT04282811
- Testing
- Venetoclax
- Where
- 27 sites in Italy
- Volunteers
- 321 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Leukemia
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia
Phase I trial to study the effectiveness of PSC-833 plus etoposide and mitoxantrone in treating children who have refractory or relapsed acute leukemia.
- Trial name
- NCT00002912
- Testing
- etoposide, mitoxantrone hydrochloride, valspodar
- Where
- 55 sites in United States, Australia and 1 more
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00002481
- Testing
- cisplatin, cyclophosphamide, cytarabine
- Where
- United States
- Sponsor
- St. Luke's Medical Center
Hairy Cell Leukemia (HCL)
Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab
The study will test the effectiveness (rate of complete remissions, total remission rate and duration of remission) and toxicity of the combined immuno/chemotherapy with subcutaneous cladribine (LITAK®) plus anti-CD20* antibody…
- Trial name
- NCT02157181
- Testing
- 2CdA +/- Rituximab
- Where
- 47 sites in Germany
- Volunteers
- 89 people
- Sponsor
- Jurgen Barth
Advanced Malignant Neoplasm, Acute Myeloid Leukemia
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
In this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for the first time. The trial includes a Main Study and four sub-studies.
- Conditions
- Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia
- Trial name
- NCT04067336
- Testing
- Ziftomenib, Midazolam, Itraconazole
- Where
- 43 sites in United States, Belgium and 5 more
- Volunteers
- 263 people
- Sponsor
- Kura Oncology, Inc.
FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of quizartinib when given in combination with azacitidine or cytarabine in treating patients with acute myeloid leukemia or myelodysplastic syndrome that have come back…
- Conditions
- FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia
- Trial name
- NCT01892371
- Testing
- Azacitidine, Cytarabine, Quizartinib
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
B-cell Acute Lymphoblastic Leukemia
The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
This is a study for patients who have been previously treated for B-ALL. The purpose of this study is to determine the safety and feasibility of CART-19 cells to the patients with relapsed and refractory CD19+ B-ALL.
- Trial name
- NCT02924753
- Testing
- Cyclophosphamide, Fludarabine, CART-19 cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Multiple Myeloma, Plasma Cell Leukemia
CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia
- Trial name
- NCT05822037
- Testing
- CT0594CP
- Where
- China
- Volunteers
- 6 people
- Sponsor
- The First Affiliated Hospital of Soochow University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.